Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Composite photo, with a doctor and a patient, and a view over the river in the Sekong Province, Lao PDR © Nature & James Callery
Left: A TACT-CV study doctor examines a patient. Right: The Sekong River in Cambodia, near the location of a TACT study site.

Published in The Lancet Infectious Diseases, the results of the MORU-led TACT-CV study demonstrate that AL+AQ  provides an alternative first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion (GMS), and could prolong the therapeutic lifetime of artemether–lumefantrine in malaria-endemic populations in SE Asia and elsewhere, with an expected longer therapeutic lifetime than current artemisinin combination therapies.

“This is an important study, showing that artemether-lumefantrine-amodiaquine is efficacious and safe for the treatment of falciparum malaria in an area of multidrug resistance. It is currently the most advanced triple ACT, which will become available as a fixed dose drug combination later this year.,” said Professor Arjen Dondorp, Head of Malaria at MORU and TACT-CV Principal Investigator (PI).

Artemisinin-based combination therapies (ACTs) are the first-line treatment for falciparum malaria, but parasites that are resistant to artemisinin and the partner drugs used in ACTs have emerged, with high levels of resistance noted in the Greater Mekong subregion in countries such as Cambodia and Vietnam. Resistance to artemisinin and ACT partner drugs has been reported widely from Cambodia and Vietnam since 2009, with a single artemisinin-resistant parasite lineage carrying the C580Y pfkelch13mutation becoming the predominant artemisinin-resistant strain by 2016-17. Artemisinin could be given with two partner drugs, lumefantrine and amodiaquine (AQ), as a triple ACT to improve cure rates and extend the useful therapeutic lifetimes of these available drugs.

The first randomised trial of artemether-lumefantrine (AL) alone versus artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance, the TACT-CV study was funded by the Bill & Melinda Gates Foundation and Wellcome, and undertaken from 2018-20 at two sites in Cambodia and one in Vietnam. Led by PI Prof Arjen Dondorp, TACT-CV was coordinated by Lorenz von Seidlein, Tom Peto, James Callery and Rupam Tripura, in collaboration with colleagues from the Cambodian malaria control programme (led by Dr Soley and Dr Chea) and OUCRU in Vietnam (led by Dr Hien and Dr Nghia).

The study showed that although AL alone cleared the initial artemisinin-resistant infections, it had only about 90% efficacy against recrudescence; for such infections, triple therapy with AL+AQ is a safe option that might be about 96% effective against recrudescence. The addition of AQ to AL did not affect plasma lumefantrine concentrations but, as in a previous trial (TRACII), it slightly increased the incidence of vomiting and mild bradycardia.

The TACT-CV team wish to thank and extend a big appreciation to everyone who was involved in successfully completing the TACT-CV study.

- Text and photos courtesy of James Callery,
on behalf of Tom Peto, Rupam Tripura and the TACT-CV team.

Read the publication 'Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial' on the Lancet Infectious Diseases website

Similar stories

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allowed researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Picturing Health: The Burden of Leprosy in Eastern Indonesia

The Eijkman Oxford Clinical Research Unit in Indonesia and Sumba Foundation collaborated with photographer Yoppy Pieter to express the human face of leprosy in Sumba, a remote island in eastern Indonesia. The project aimed to visualize the story of leprosy and raise awareness of this debilitating and heavily stigmatised disease

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Research Culture at OUCRU

What do we mean by 'Research Culture' and how has fostering a multinational, collaborative culture helped us deliver world-class research? Let's explore the research culture at OUCRU.

Policy and Public Engagement at OUCRU

Why does OUCRU place an important focus on engaging with its important partners, policy makers, the press, the community, and young people? Explore our work in policy & public engagement.